PATENT CLAIM ANALYSIS

Application Number: 16024514
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-06
Patent Classification: ["544", "350000"]

Abstract:
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Claim (Index 70):
The method according to  claim 69 , wherein the activity of the one or more of ErbB 1, ErbB2, or ErbB4, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys797 of ErbB1, Cys805 of ErbB2 or Cys803 of ErbB4.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.05882
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15221421', '13671129', '15080351', '13670937', '13667396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8646926246450736
- 35 USC 102 Novelty (BERT): 0.6094988234693919
- Combined Prediction Score: 0.8391732445275054
- Mean Citation Score: 500.563732
- Max Citation Score: 500.59354
- Similarity Product: 366.5590701739145

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test